Filing Flows › Korro Bio (KRRO) › Q4 2024
Korro Bio (KRRO) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 18, 2025
Korro Bio (KRRO) reported revenue of $2.3M for the fourth quarter 2024 (Q4 2024).
Korro Bio, Q4 2024: revenue $2.3M, net loss $21.2M, operating cash flow −$7.5M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.3M | — | — |
| Operating profit | −$23.0M | — | — |
| Net earnings | −$21.2M | — | — |
| Operating cash flow | −$7.5M | — | — |
What changed
Revenue was $2.3M in Q4 2024.
Operating costs exceeded revenue by $23.0M, an operating margin of -1014.5%. The quarter ended with a net loss of $21.2M.
Operating cash flow was −$7.5M. Non-cash charges added back $1.3M of depreciation and $1.4M of share-based compensation. Working capital and other items added $11.1M. Capital expenditures of $1.5M exceeded it, leaving free cash flow of −$8.9M.
Questions
What was Korro Bio's revenue in the fourth quarter 2024?
Korro Bio (KRRO) reported revenue of $2.3M for the fourth quarter 2024 (Q4 2024).
Source: Korro Bio 10-K on SEC EDGAR.